Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
My previous session
Most popular
  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2019 909 B
EBIT 2019 -
Net income 2019 61 588 M
Finance 2019 399 B
Yield 2019 1,88%
Sales 2020 915 B
EBIT 2020 -
Net income 2020 60 605 M
Finance 2020 411 B
Yield 2020 1,88%
P/E ratio 2019 39,38
P/E ratio 2020 39,69
EV / Sales2019 2,46x
EV / Sales2020 2,43x
Capitalization 2 633 B
More Financials
Company
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.7%): prescription medicines (93% of net sales) and OTC medicines (7%) primarily for the treatment of thrombotic disorders,... 
Sector
Pharmaceuticals
Calendar
03/11 | 01:10pmPresentation
More about the company
Surperformance© ratings of DAIICHI SANKYO COMPANY, LI
Trading Rating : Investor Rating :
More Ratings
Latest news on DAIICHI SANKYO COMPANY, LI
02/05DAIICHI SANKYO : FDA Grants Priority Review for Daiichi Sankyo's New Drug Applic..
PU
02/01DAIICHI SANKYO : Announces Transfer of Daiichi Sankyo Propharma Takatsuki Plant ..
AQ
01/31DAIICHI SANKYO : Announces Transfer of Daiichi Sankyo Propharma Takatsuki Plant ..
PU
01/16SOL GEL TECHNOLOGIES : Appoints John Vieira as U.S. Head of Commercialization
AQ
01/14DAIICHI SANKYO : Initiates Pivotal Phase 3 Trial of Trastuzumab Deruxtecan (DS-8..
PU
01/09DAIICHI SANKYO : Mitsubishi UFJ Capital and Tokyo Institute of Technology Announ..
PU
01/09DAIICHI SANKYO : Pediatric Dosage and Administration Approved for Anti-epileptic..
AQ
01/09EXELIXIS : Daiichi Sankyo Announces Approval of MINNEBRO Tablets for the Treatme..
AQ
01/09DAIICHI SANKYO : Announces Marketing Approval in Japan of 'Tarlige Tablets' for ..
AQ
01/09EXELIXIS' : Collaborator Daiichi Sankyo Receives Regulatory Approval for MINNEBR..
AQ
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LI
More recommendations
Sector news : Pharmaceuticals - NEC
02/15BRISTOL MYERS SQUIBB : Starboard gauges Bristol-Myers shareholder support for Ce..
RE
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -2-
DJ
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -- Journal Report
DJ
02/15WSJ TAX GUIDE 2019 : The Drug Industry -- Journal Report
DJ
More sector news : Pharmaceuticals - NEC
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
DAIICHI SANKYO COMPANY, LIMITED Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DAIICHI SANKYO COMPANY, LI
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 4 473  JPY
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Joji Nakayama Chairman & CEO
Sunao Manabe President, COO & Representative Director
Toshiaki Sai CFO, Representative Director & Vice President
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Katsumi Fujimoto Director & Senior Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED8.44%23 834
JOHNSON & JOHNSON4.08%365 768
PFIZER-3.85%245 920
ROCHE HOLDING LTD.11.98%233 242
NOVARTIS7.19%228 685
MERCK AND COMPANY4.45%207 536